within Pharmacolibrary.Drugs.ATC.R;

model R01AB03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.9999999999999998e-05,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R01AB03</td></tr><td>route:</td><td>ocular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tetryzoline (also known as tetrahydrozoline) is an imidazoline derivative acting as an alpha-adrenergic receptor agonist, primarily used as a topical decongestant in ophthalmic (eye drop) and nasal preparations for relief of redness or nasal congestion. It is still an approved medication in many countries.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed human pharmacokinetic models or clinical PK parameter studies are published for tetryzoline. The following are rough estimates based on known drug class properties (topical ocular/nasal imidazoline alpha agonists) and limited animal/toxicological data.</p><h4>References</h4><ol><li><p>Okur, NÜ, et al., &amp; Okur, ME (2020). In vitro-in vivo evaluation of tetrahydrozoline-loaded ocular in situ gels on rabbits for allergic conjunctivitis management. <i>Drug development research</i> 81(6) 716–727. DOI:<a href=&quot;https://doi.org/10.1002/ddr.21677&quot;>10.1002/ddr.21677</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32359095/&quot;>https://pubmed.ncbi.nlm.nih.gov/32359095</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R01AB03;
